2022
Pathophysiology and management of hypoglycemia in diabetes
Sanchez‐Rangel E, Deajon‐Jackson J, Hwang JJ. Pathophysiology and management of hypoglycemia in diabetes. Annals Of The New York Academy Of Sciences 2022, 1518: 25-46. PMID: 36202764, DOI: 10.1111/nyas.14904.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusCounter-regulatory hormonal responsesMechanism of hypoglycemiaDuration of diabetesManageable chronic diseaseOptimal glycemic controlManagement of hypoglycemiaTreatment of hypoglycemiaNew insulin formulationsDiscovery of insulinGlycemic controlDiabetes mellitusTherapeutic optionsBrain glucoseChronic diseasesNovel therapiesDiabetes managementHypoglycemiaPharmacologic targetHormonal responsesInsulin formulationsDiabetesPatientsCurrent literatureDelivery devicesReversibility of brain glucose kinetics in type 2 diabetes mellitus
Sanchez-Rangel E, Gunawan F, Jiang L, Savoye M, Dai F, Coppoli A, Rothman DL, Mason GF, Hwang JJ. Reversibility of brain glucose kinetics in type 2 diabetes mellitus. Diabetologia 2022, 65: 895-905. PMID: 35247067, PMCID: PMC8960594, DOI: 10.1007/s00125-022-05664-y.Peer-Reviewed Original ResearchConceptsType 2 diabetesBrain glucose levelsGlucose levelsHyperglycaemic clampGlycaemic controlBrain glucoseUncontrolled type 2 diabetesType 2 diabetes mellitusConclusions/interpretationThese findingsAims/hypothesisWePlasma glucose levelsLinear mixed-effects regression modelsMixed-effects regression modelsContinuous glucose monitoringMinimal weight changeMagnitude of improvementAge 44.8MethodsEight individualsSD HbA1cDiabetes mellitusCerebral glucoseInterpretationThese findingsWeek interventionRegimen intensificationPost intervention
2019
PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes
Bini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. Journal Of Nuclear Medicine 2019, 61: 570-576. PMID: 31601695, PMCID: PMC7198375, DOI: 10.2967/jnumed.119.234013.Peer-Reviewed Original ResearchConceptsT1DM individualsHealthy controlsDopamine DOutcome measuresAcute C-peptide responseSUVR-1Type 1 diabetes mellitusPET/CT scanningDuration of diabetesMaximal glycemic potentiationC-peptide responseClinical outcome measuresInsulin secretory capacityRoutine clinical measuresD3 receptor densityΒ-cell functionC-peptide releaseQuantitative PET measuresΒ-cell massDynamic PET scansQuantitative outcome measuresAgonist PET radioligandDiabetes mellitusReceptor agonistInsulin antibodies
2018
Glycemic Variability and Brain Glucose Levels in T1DM
Hwang JJ, Jiang L, Sanchez Rangel E, Fan X, Ding Y, Lam W, Leventhal J, Dai F, Rothman DL, Mason GF, Sherwin RS. Glycemic Variability and Brain Glucose Levels in T1DM. Diabetes 2018, 68: db180722. PMID: 30327383, PMCID: PMC6302539, DOI: 10.2337/db18-0722.Peer-Reviewed Original ResearchConceptsBrain glucose levelsGlycemic variabilityGlucose levelsHyperglycemic clampType 1 diabetes mellitusPlasma glucose levelsBrain glucose transportHealthy control participantsDiabetes mellitusBrain glucoseControl ratsContinuous glucose monitorGlucose clampRat modelOccipital lobeMRS scanningT1DMGlucose kineticsControl participantsGlucose transport kineticsGlucose monitorSimilar changesRatsClampGlucose transport
2017
Metformin: clinical use in type 2 diabetes
Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia 2017, 60: 1586-1593. PMID: 28770321, DOI: 10.1007/s00125-017-4336-x.Peer-Reviewed Original ResearchConceptsGlucose-lowering effectType 2 diabetesModerate chronic kidney diseaseOral glucose-lowering medicationsNew glucose-lowering drugsType 2 diabetes mellitusOptimal initial therapyGlucose-lowering medicationsChronic kidney diseaseFirst-line treatmentGlucose-lowering drugsGood safety profilePrecise mechanismHepatic glucose productionMore robust evidenceFoundation therapyInitial therapyCardiovascular eventsInflammatory markersRenal dysfunctionDiabetes mellitusWeight neutralityKidney diseaseSafety profileGlucose production